<!DOCTYPE html>
<html lang="en">
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title></title>
    <link rel="stylesheet" href="css/as.css" type="text/css" />
    <link rel="stylesheet" href="css/animate.css" type="text/css" />
    <script type="text/javascript" src="js/base_presentation.js"></script>
    <script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">

        //delay = 500;
        ANIMATION = [
        //'.chartbk, .title',
                 maskY('.blueline, .greenline'),
				fade('.greenline-labels, .blueline-labels'),

		   ];
    </script>
</head>
<body class="slide-2">
    <div id="content">
        <div class="collage">
        </div>
        <header>
ARTEMIS: Majority of patients in both arms achieved<br>viral load &lt;50 copies/mL at 48 weeks

</header>
        <div class="logo">
        </div>
        <section>

<article>
	<div class="chartwrap">
    	<div class="chartbk"></div>
        <div class="title">Percent of patients with HIV RNA &lt;50 copies/mL<br>at 48 weeks (per protocol, TLOVR)<sup>*3,4</sup></div>
    	<div class="blueline"></div>
        <div class="blueline-labels">78</div>
        <div class="greenline"></div>
        <div class="greenline-labels">84</div>
		<div class="disc1">Estimated difference in response versus KALETRA for non-inferiority: PP=5.6% (95% CI: -0.1, 11) p&lt;0.001.<br/>
			Estimated difference in response vs KALETRA for superiority: ITT=5.5%<br/> (95% CI: -0.3, 11) p=0.062
			</div>
		<div class="disc" style="top:345px; left: 180px;">n=346</div>
		<div class="disc" style="top:345px; left: 350px;">n=343</div>
		<div class="disc">*Per-protocol time-to-loss of virologic response (PP-TLOVR) algorithm was used to assess virologic response<br>(HIV-1 &lt;50 copies/mL). If non-inferiority was established, superiority testing would be performed in the intent-to-treat<br>(ITT) population.</div>

    </div>

</article>

<aside>

<p class="bullet">In treatment-naïve patients, DRV/RTV<br>was non-inferior to KALETRA<br>treatment for the primary endpoint at<br>Week 48 (per protocol).</p>
<p class="bullet">At week 48, virologic failure occurred<br>in 34 (10%) DRV/RTV patients<br>and 49 (14%) KALETRA patients.</p>

</aside>

</section>
        <div class="buttonwrap">
            <button id="88" data-placement="top" onclick="makecall('PopupWithHeader',Array('as-02-popup-01','Study Design','<table width=\'900px\'><tr align=\'center\'><td class=\'reference\'>ARTEMIS Study Design<sup>2,3</sup></td></tr></table>','90','625','10','0','900','500','1','0','1','0'),this);">
                Study Design</button>
        </div>
        <footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>
    </div>
</body>
</html>